Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 11.37
(-0.26%)
CNY 11.37
(-0.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 331.14 Million CNY | -59.49% |
| 2022 | 817.39 Million CNY | -32.67% |
| 2021 | 1.21 Billion CNY | 22.67% |
| 2020 | 989.69 Million CNY | 42.23% |
| 2019 | 695.83 Million CNY | 16.31% |
| 2018 | 598.24 Million CNY | 17.77% |
| 2017 | 507.99 Million CNY | 26.04% |
| 2016 | 403.04 Million CNY | 33.32% |
| 2015 | 302.32 Million CNY | 3.18% |
| 2014 | 293 Million CNY | 16.33% |
| 2013 | 251.87 Million CNY | 24.8% |
| 2012 | 201.81 Million CNY | 32.14% |
| 2011 | 152.73 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 131.95 Million CNY | 425.73% |
| 2024 Q2 | 86.6 Million CNY | -34.37% |
| 2024 Q3 | 94.5 Million CNY | 9.13% |
| 2023 Q4 | 25.09 Million CNY | -78.66% |
| 2023 Q1 | 140.3 Million CNY | 5.55% |
| 2023 Q2 | 48.09 Million CNY | -65.72% |
| 2023 Q3 | 117.63 Million CNY | 144.58% |
| 2023 FY | 331.14 Million CNY | -59.49% |
| 2022 Q2 | 221.29 Million CNY | -11.67% |
| 2022 Q1 | 250.52 Million CNY | 26.96% |
| 2022 FY | 817.39 Million CNY | -32.67% |
| 2022 Q4 | 132.92 Million CNY | -37.49% |
| 2022 Q3 | 212.64 Million CNY | -3.91% |
| 2021 Q1 | 391.72 Million CNY | 59.87% |
| 2021 Q4 | 197.33 Million CNY | -42.04% |
| 2021 FY | 1.21 Billion CNY | 22.67% |
| 2021 Q3 | 340.44 Million CNY | 19.64% |
| 2021 Q2 | 284.55 Million CNY | -27.36% |
| 2020 Q1 | 102.56 Million CNY | -15.49% |
| 2020 FY | 989.69 Million CNY | 42.23% |
| 2020 Q4 | 245.02 Million CNY | -28.76% |
| 2020 Q3 | 343.94 Million CNY | 15.35% |
| 2020 Q2 | 298.16 Million CNY | 190.7% |
| 2019 Q4 | 121.36 Million CNY | -41.22% |
| 2019 Q3 | 206.48 Million CNY | 0.05% |
| 2019 Q2 | 206.38 Million CNY | 27.72% |
| 2019 FY | 695.83 Million CNY | 16.31% |
| 2019 Q1 | 161.59 Million CNY | 31.64% |
| 2018 Q4 | 122.75 Million CNY | -22.26% |
| 2018 Q2 | 182.81 Million CNY | 35.65% |
| 2018 Q1 | 134.76 Million CNY | 3.07% |
| 2018 FY | 598.24 Million CNY | 17.77% |
| 2018 Q3 | 157.9 Million CNY | -13.62% |
| 2017 Q1 | 102.97 Million CNY | 13.06% |
| 2017 Q2 | 134.26 Million CNY | 30.39% |
| 2017 FY | 507.99 Million CNY | 26.04% |
| 2017 Q3 | 140 Million CNY | 4.27% |
| 2017 Q4 | 130.75 Million CNY | -6.61% |
| 2016 Q3 | 100.93 Million CNY | -17.2% |
| 2016 FY | 403.04 Million CNY | 33.32% |
| 2016 Q4 | 91.07 Million CNY | -9.77% |
| 2016 Q2 | 121.91 Million CNY | 36.8% |
| 2016 Q1 | 89.11 Million CNY | 27.44% |
| 2015 Q2 | 104.64 Million CNY | 74.0% |
| 2015 Q1 | 60.13 Million CNY | -11.44% |
| 2015 FY | 302.32 Million CNY | 3.18% |
| 2015 Q4 | 69.92 Million CNY | 3.43% |
| 2015 Q3 | 67.61 Million CNY | -35.39% |
| 2014 FY | 293 Million CNY | 16.33% |
| 2014 Q4 | 67.91 Million CNY | -4.49% |
| 2014 Q1 | 57.34 Million CNY | 0.0% |
| 2014 Q3 | 71.1 Million CNY | -26.43% |
| 2014 Q2 | 96.64 Million CNY | 68.54% |
| 2013 FY | 251.87 Million CNY | 24.8% |
| 2012 FY | 201.81 Million CNY | 32.14% |
| 2011 FY | 152.73 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 66.824% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 86.685% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | -11.544% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | 44.24% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | -18.64% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | 39.697% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | -677.34% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | -119.812% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | -9.925% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 343.805% |